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health care payer in patients with ﬂuoropyrimidine, irinotecan
and oxaliplatin refractory advanced colorectal cancer.
METHODS: Data on management and resource utilization were
collected using a two round questionnaire send to a representa-
tive expert panel. Patients with 10% and those with 1–10 %
EGFR expressing tumour cells were considered separately as the
latter are theoretically excluded from reimbursement for cetux-
imab, the currently available EGFR directed agent in Belgium.
In the second round, the average, 10 and 90 percentile values of
the responses collected in the ﬁrst round were sent to each expert
who could revise his original answer, acknowledge the average
value or provide a new estimate and rank his answers on a
(un)certainty scale. Costs were obtained by multiplying the
average resource use with the speciﬁc unit cost (ofﬁcial tariffs).
Total costs included costs related to preventive measures, adverse
events, treatment evaluation and symptom control per treatment
cycle (4 or 6 w). RESULTS: Ten different treatment options were
deﬁned by the experts. If EGRF-expressing of the tumour is
10%, Irinotecan-Cetuximab is the treatment of choice in 87%
of patients and responsible for 98% of the total cost of €16,611
(95%CI:€13,271–€20,234). If EGFR-expression of the tumour is
between 1 and 10%, 48% of patients are treated by BSC alone.
BSC is responsible for 18% of the mean overall cost of €6465 per
3 months (95%CI:€4456–€8851) for a patient in this setting.
5FU-MitomycinC is the most used chemotherapy regimen in this
setting (26.04%). CONCLUSIONS: The majority of irinotecan
refractory colorectal cancer patients with a10% EGFR expres-
sion are having further active treatment with irinotecan-
cetuximab responsible for 98% of total costs. In the 1–10 %
EGFR group BSC is the most used treatment option.
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OBJECTIVES: High-risk human papilloma viruses (HPV) can
cause cervical cancer and are associated with high-grade vaginal
and vulvar lesions (especially in younger women). The objective
of the current study was to assess the economic burden of disease
for these lesions in one German hospital. METHODS: Each
patient who received at least one surgical intervention was
included in the analysis. A retrospective analysis from patient
ﬁles was conducted to determine the consumption of resources
and direct medical cost for treatment of 94 women for VIN and
VaIN 2–3 in the Department of Obstetrics and Gynecology at the
University of Düsseldorf, Germany, between 1991 and 2008
analysed retrospectively from the patients’ dossiers. The main
analysis evaluated the costs for surgical interventions and outpa-
tient visits for one year following surgery. RESULTS: A total of
113 surgical interventions (60 in-patient, 53 out-patient) were
performed. 55% of the patients had one intervention and 45%
had more than one interventions. The most frequent interven-
tions were biopsy (77%) and laser vaporisation (72%). There
were 166 out-patient visits with 137 colposcopies, 110 smears
and 60 biopsies. The average direct medical costs were 1355.49€
per patient for in-patient treatment and 208.76 € per patient for
out-patient treatment. The average direct costs for outpatient
visits in the dysplasia clinic were 59.14 € per patient. Adding
indirect costs for sick leave into the main analysis, the average
costs increased to 3451.51 € per patient. CONCLUSIONS: This
analysis provides the ﬁrst estimation of the economic burden of
high-grade vaginal and vulvar lesions in German health care
system. HPV vaccination could prevent half of the high-grade
vaginal and vulvar lesions and could signiﬁcantly reduce the
treatment costs for by these lesions.
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OBJECTIVES: To describe the management of patients with
malignant ascites and to evaluate resource consumption and
associated cost from the hospital provider’s perspective in a pilot
study. METHODS: A cross-sectional, retrospective pilot study
was performed at hospitals of maximum medical care in
Germany. Resource consumption data for e.g. number of para-
centeses, length of hospital stay, diagnostics and drugs were
obtained by patient chart abstraction. Direct medical cost was
calculated. RESULTS: In total, 27 patients with 94 hospital stays
were included in the analysis (mean age 63 years, standard
deviation [SD] 15; 56% male, mean Karnofsky index 54% SD
25). The most common underlying malignancies were gastric
carcinoma (26%), pancreatic carcinoma (15%) and colon car-
cinoma (11%). Mean number of therapeutic paracenteses per
patient was 4.5 (SD 3.8) within the time period from ascites
diagnosis to death. Mean length of hospital stay was 5.5 days
(SD 8.0). Medication mainly comprised human albumin (64%),
diuretics (20%), antibiotics (5%) and cytostatics used for intra-
peritoneal chemotherapy (3%). Mean direct cost per patient and
per hospital stay was €738 (SD1258) and €1011 (SD1584) per
hospital stay with paracentesis as reason for admission. Mean
cost per patient was €2540 (SD 2808). If cost calculation is
based on unit cost for German university hospitals, costs were
18% higher. Main cost driver was the hospital stay (60% of
costs). CONCLUSIONS: Management of malignant ascites
varies with respect to in- or outpatient paracentesis, number of
paracenteses, and concomitant medication. More data are
needed to optimize management and identiﬁcation of cost effec-
tive therapeutic options. In the ﬁeld of palliative care investiga-
tion of resource consumption and costs is challenging since the
needs and quality of life of the patients should always be taken
into consideration.
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OBJECTIVES: To evaluate the treatment cost of IFIs by compar-
ing subjects who developed a proven or probable IFI to matched
controls who did not. METHODS: Data were obtained by ret-
rospective chart review in German hospitals using a non-
randomized parallel group design in patients who have
undergone remission induction chemotherapy for newly diag-
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nosed or for ﬁrst relapse of AML or MDS. IFI subjects had been
diagnosed with proven or probable IFI according to EORTC
criteria and received antifungal therapy. Match criteria were
duration of febrile neutropenia, age and type of chemotherapy.
Resource utilization data included length of stay, mechanical
ventilation, parenteral nutrition, diagnostic procedures, antifun-
gal agents and cost-intensive concomitant medication. Direct
medical cost was calculated from the hospital provider perspec-
tive. RESULTS: A total of 108 patients were enrolled at 5
maximum care hospitals, 36 IFI patients and 72 controls. Mean
age was 61.5 years (IFI group) and 61.2 years (control group),
50% and 63% were male, respectively. Primary diagnosis was
AML in 97% of IFI patients and in 99% of control patients. The
vast majority of IFI patients (74%) had invasive aspergillosis. IFI
patients stayed on average 12 days longer in the hospital than
control patients. In the IFI group all patients (100%) and in the
control group 89% of patients received antifungal drugs. Mean
direct cost per patient amounted to €51,517 in the IFI group and
€30,454 in the control group. Incremental cost of €21,063 was
dominated by cost for antifungal drugs (36%), hospital stay
(32%) and blood products (23%). CONCLUSIONS: The eco-
nomic burden of IFI in patients with AML or MDS is remarkable
from the perspective of hospitals in Germany. Therefore, anti-
fungal prophylaxis in patients with AML or MDS should be
considered because of clinical and economic reasons.
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OBJECTIVES: Treatment regimens in extensively pre-treated
advanced and metastatic breast cancer (MBC) patients may
confer similar efﬁcacy but have different toxicity proﬁles. This
study aimed to identify toxicities associated with chemotherapy
regimens in late-line breast cancer and to estimate direct costs of
managing those toxicities. METHODS: A PubMed search iden-
tiﬁed global Phase II/III studies of single agent and combination
treatment regimens for advanced and MBC patients previously
treated with 2 chemotherapy regimens. The proportion of
patients experiencing grade 3 and 4 toxicities was abstracted.
Using expert opinion, reported toxicities were placed into repre-
sentative groupings based on similarities in event types and treat-
ment costs (e.g., extremity pain, pain, arthralgia, headache) and
a proxy for each grouping (e.g., pain) was identiﬁed for purposes
of estimating direct costs of treatment for grade 3 and grade 4
(inpatient) toxicities. Unit costs were estimated using data from
Health Care Utilization Project, Medicare reimbursement rates,
and Redbook and updated to 2008 USD using the medical care
component of the Consumer Price Index. RESULTS: This study
included toxicity information from seven treatment regimens
studied in the salvage setting. The most commonly reported
grade 3 toxicities were hematological (albumin-bound paclitaxel,
capecitabine, gemcitabine, ixabepilone + capecitabine), cardiac
(bevacizumab + capecitabine), fatigue (ixabepilone), and
gastrointestinal-related (sunitinib). The most commonly reported
grade 4 toxicities were hematological (albumin-bound paclitaxel,
capecitabine, ixabepilone, ixabepilone + capecitabine), embolic
(bevacizumab + capecitabine) and anemia-related (capecitabine,
gemcitabine). Estimated total direct costs of treating all toxicities
by treatment regimen were: sunitinib ($107), gemcitabine
($585), albumin-bound paclitaxel ($1446), bevacizumab +
capecitabine ($3493), capecitabine ($3775), ixabepilone
($4403), and ixabepilone + capecitabine ($16279). CONCLU-
SIONS: Treatment regimens in extensively pre-treated breast
cancer patients may have similar efﬁcacy but vary greatly in the
cost of managing treatment-related toxicities: $107 to $16279 in
this study. The costs of these toxicities should be included in
future economic evaluations comparing the clinical and cost-
effectiveness of alternative treatment regimens for advanced and
MBC.
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OBJECTIVES: To estimate the costs of infusional 5-ﬂuorouracil
(5-FU) and oral capecitabine (CAP) in Metastatic Colorectal
Cancer (MCC) patients. METHODS: Observational, retrospec-
tive study estimating direct medical costs (medications, adminis-
tration patterns, infusion device insertion, tests, visits, adverse
event management) after treatment with ﬁrst-line 5-FU or CAP,
with or w/o association of other chemotherapies. Data were
collected from patients’ charts in 5 Oncology ambulatories.
Average per patient direct cost was estimated by national tariffs
and market retail prices (2007 values) in the Italian Healthcare
Service (IHCS) perspective. RESULTS: Data were collected on
202 subjects (136 on 5-FU; 66 on CAP). A total of 93% 5-FU-
patients and 47% CAP-patients received infusional chemo-
therapy agents in association. Alternatives differed in the mean
number of cycles planned (5-FU 10.7 vs CAP 6.7) and adminis-
tered (5-FU 9.7 vs CAP 6.4). In the IHCS perspective, average
total cost was €12,029 (SD €5,521) per 5-FU-patient vs. €5,781
(SD €4,933) per CAP-patient; considering only patients in com-
bination regimens mean total cost per patient were €12,534 in
5-FU plus oxaliplatin or irinotecan and €9,986 in CAP plus
oxaliplatin or irinotecan. Administration of infusional therapy in
Day Hospital (DH) accounted for 51% and 28% of total costs in
5-FU and CAP group, respectively; drug cost amounted to 37%
in 5-FU and 60% CAP arm. Arms differed as to catheter inser-
tion, adverse event management and chemo-supportive therapy
costs. Oral route remained the most economic alternative over
the infusional route in all sensitivity analyses. CONCLUSIONS:
Management of MCC patients by oral chemotherapies may be
economically rational to IHCS.
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OBJECTIVES: To quantify the ﬁnancial impact of home care
support teams versus inpatient palliative care in a university
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